Charles Schwab Investment Management Inc. Has $12.27 Million Position in CG Oncology, Inc. (NASDAQ:CGON)

Charles Schwab Investment Management Inc. raised its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 12.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 427,760 shares of the company's stock after purchasing an additional 48,096 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.56% of CG Oncology worth $12,268,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. State Street Corp boosted its stake in CG Oncology by 73.0% during the 3rd quarter. State Street Corp now owns 1,700,653 shares of the company's stock valued at $64,166,000 after purchasing an additional 717,722 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of CG Oncology by 575.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 746,063 shares of the company's stock valued at $28,149,000 after purchasing an additional 635,653 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of CG Oncology by 96.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,078,527 shares of the company's stock worth $40,701,000 after purchasing an additional 528,749 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of CG Oncology by 153.4% in the 3rd quarter. Wellington Management Group LLP now owns 510,219 shares of the company's stock worth $19,251,000 after purchasing an additional 308,852 shares in the last quarter. Finally, FMR LLC boosted its holdings in CG Oncology by 83,581.6% during the third quarter. FMR LLC now owns 145,606 shares of the company's stock worth $5,494,000 after buying an additional 145,432 shares in the last quarter. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts have recently commented on CGON shares. TD Cowen assumed coverage on CG Oncology in a research report on Tuesday, January 7th. They set a "buy" rating for the company. Royal Bank of Canada restated an "outperform" rating and issued a $66.00 price target on shares of CG Oncology in a research report on Friday, December 6th. HC Wainwright reissued a "buy" rating and set a $75.00 target price on shares of CG Oncology in a research note on Tuesday. Finally, Morgan Stanley reiterated an "overweight" rating and set a $55.00 price target on shares of CG Oncology in a report on Friday, March 7th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $63.88.

CG Oncology Trading Down 3.5 %

Shares of NASDAQ:CGON traded down $0.99 during trading on Tuesday, reaching $27.54. The stock had a trading volume of 577,070 shares, compared to its average volume of 634,301. The stock has a fifty day simple moving average of $28.08 and a two-hundred day simple moving average of $32.09. CG Oncology, Inc. has a 52 week low of $23.91 and a 52 week high of $46.99.

Insider Transactions at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.